FDA
-
-
-
-
-
-
-
Voyager presents positive safety data for Alzheimer's gene therapy VY1706
-
-
-
-
-
-
-
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
-
-
-
-
-
-
-
Voyager Therapeutics (VYGR) Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
-
-
-
-
-
-
-
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
-
-
-
-
-
-
-
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
-
-
-
-
-
-
-
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
-
-
-
-
-
-
-
Neurocrine Bio (NBIX), Voyager (VYGR) Present New L-T 3-Year Data Demonstrating that One-Time Treatment with Investigational Gene Therapy Showed Sustained Improvement in Motor Function
-
325,591 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

